Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain

December 28, 2017 updated by: William McKay, University of Saskatchewan
Oral medications like gabapentin and acetaminophen are commonly given to patients prior to surgery to provide balanced anaesthesia. Intravenous methadone has been shown to decrease postoperative pain as well as postoperative nausea and vomiting, which are known barriers to discharge. Oral methadone would be a convenient alternative to give as a preoperative medication with its bioavailability approaching 80%. No clinical trials to date have explored the utility of oral methadone as a preoperative analgesic to improve postoperative outcomes. Current literature shows preoperative IV methadone reduces opioid consumption in the perioperative period for cardiac surgeries; therefore, investigators hypothesize that preoperative oral methadone will also reduce postoperative pain and opioid consumption in patients undergoing sternotomy for cardiac surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Investigators propose a prospective, randomized, double-blind, placebo-controlled trial to investigate the effects of preoperative oral methadone on postoperative pain. The trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and University of Saskatchewan Research Ethics Committee principles using an intent-to-treat model. The primary endpoint will be postoperative pain in the ICU, and secondary outcomes will include morphine requirements as measured by Patient Controlled Analgesia (PCA). Secondary endpoints include opioid consumption at 15 minutes and at 2, 4, 8, 12, 24, 48, and 72 hours post extubation. Other secondary endpoints include the following: pain with cough (using a 0-10 verbal pain scale) measured at the time of extubation then daily until post-op day three. Secondary outcomes that will be recorded from nursing assessment records include: incidence of nausea and/or vomiting requiring antiemetics, pruritus, hypoventilation (respiratory rate less than 8 breaths/min), hypoxemia (oxygen saturation less than 90%), time to extubation, and sedation (Richmond Agitation-Sedation Scale of -4 or -5).

Patients will receive a dose of either oral methadone or placebo prior to entering the operating room. The dose given will be 0.3 mg/kg (to a maximum of 30 mg) or equivalent volume of placebo. An blinded research assistant will receive an envelope the morning of surgery outlining if the patient is in group A or B as well as their weight in kg. For the methadone arm the research assistant will prepare the appropriate amount of methadone, which is dispensed as 10 mg/mL, and dilute it to a total volume of 5 mL in sugary syrup to mask its taste. For the placebo arm a similar volume will be mixed at a 0.3 mg/kg volume and diluted to a total volume of 5 mL of sugary syrup. The methadone or placebo will be given to the researcher in a syringe. The researcher will give syringe to the patient and the patient will administer the solution to themself orally prior to entering the operating room.

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7K 5T6
        • Saskatoon Health Region, 410 22nd Street East

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • presenting for elective first-time CABG cardiac surgery with anticipated extubation within 12 hours

Exclusion Criteria:

  • < 18 years of age
  • preoperative renal failure requiring dialysis or serum creatinine greater than 176 µmol/L
  • significant hepatic dysfunction (liver function tests more than twice the upper limit of normal)
  • ejection fraction less than 30%
  • corrected QT interval (QTc) on ECG > 440ms for men and 450ms for women
  • pulmonary disease necessitating home oxygen therapy
  • preoperative requirement for inotropic agents or intra-aortic balloon pump to maintain hemodynamic stability
  • emergency surgery
  • allergy to methadone
  • use of preoperative opioids or recent history of opioid abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Methadone
Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
Placebo Comparator: Placebo
Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
equivalent volume (5mL) of syrup given preoperatively

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score (VRS)
Time Frame: 24 hours
Pain score as measured by 0-10 Verbal Rating Score (VRS)
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Morphine Consumption (mg)
Time Frame: 72 hours
Total dose in mg of IV morphine administered via Patient Controlled Analgesia
72 hours
Pain score (VRS)
Time Frame: Up to 72 hours postoperative
Pain score as measured by 0-10 Verbal Rating Score (VRS)
Up to 72 hours postoperative
Time to extubation
Time Frame: up to 24 hours postoperative
Time from start of surgery until removal of endotracheal tube in ICU
up to 24 hours postoperative
Level of sedation
Time Frame: up to 72 hours postoperative
Level of sedation as measured by the Richmond Agitation-Sedation Scale (RASS) in ICU
up to 72 hours postoperative
Incidence of opioid-related side effects
Time Frame: up to 72 hours postoperative
Incidence of as nausea, vomiting, pruritus, hypoventilation, and hypoxia during a seventy-two hour monitoring period
up to 72 hours postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: William PS McKay, MD FRCPC, Department of Anesthesiology, University of Saskatchewan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2016

Primary Completion (Actual)

August 1, 2016

Study Completion (Actual)

December 1, 2017

Study Registration Dates

First Submitted

April 6, 2016

First Submitted That Met QC Criteria

May 12, 2016

First Posted (Estimate)

May 17, 2016

Study Record Updates

Last Update Posted (Actual)

January 2, 2018

Last Update Submitted That Met QC Criteria

December 28, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Methadone

3
Subscribe